# US 10,869,918 B2 · Acinetobacter o-oligosaccharyltransferases and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,869,918 B2 - Document ID: US10869918B2 - Status: Granted - Kind: B2 - Application number: 16/390,833 - Filed: 2019-04-22 - Published: 2019-11-14 - Granted: 2020-12-22 - Earliest claimed: 2015-02-26 - Assignees: Vaxnewmo LLC - Applicants: VaxNewMo LLC - Inventors: Mario Feldman; Mohamed Adel Nasr - Web page: https://patentgrep.com/patent/US10869918B2 ## CPC - A61K 39/09: {Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus}, streptococcus - A61P 31/04: Antibacterial agents - A61P 37/04: Immunostimulants - C07K 14/315: from Streptococcus (G), e.g. Enterococci - C12N 9/1081: {transferring other glycosyl groups (2.4.99)} - C12P 21/005: {Glycopeptides, glycoproteins} - A61K 2039/6087: {Polysaccharides; Lipopolysaccharides [LPS]} - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)} - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present application provides methods and uses of O-oligosaccharyltransferase (O-OTases) for generating vaccines. In particular, the present application provides a method of synthesizing a glycoprotein comprising glycosylation of pilin-like protein ComP using a PglLComP O-OTase. Uses of glycoproteins synthesized by glycosylating ComP using PglLComP O-OTase, particularly for the preparation of vaccines and the like, including a vaccine to Streptococcus, is also provided. ## Claims ### Claim 1 A method of glycosylating a protein in a bacterial cell, the method comprising glycosylating a fusion protein comprising ComP, with an N-glycan in a bacterial cell, using a PglLComP O-oligosaccharyltransferase. ### Claim 2 (depends on 1) The method of claim 1 comprising expressing PglLComP O-oligosaccharyltransferase, the ComP fusion protein, and the N-glycan together in the bacterial cell. ### Claim 3 (depends on 1) The method of claim 1, wherein the ComP fusion protein comprises an adjuvant or carrier. ### Claim 4 (depends on 1) The method of claim 1, wherein the bacterial cell is Acinetobacter or E. coli. ### Claim 5 (depends on 1) The method of claim 1, wherein the N-glycan is derived from Campylobacter. ### Claim 6 (depends on 5) The method of claim 5, wherein the N-glycan is a Campylobacter jejuni N-heptasaccharide. ### Claim 7 (depends on 4) The method of claim 4, wherein the Acinetobacter is A. baylyi, A. baumannii, A. nosocomialis, or A. calcoaceticus. ### Claim 8 (depends on 1) A conjugate vaccine comprising the glycosylated ComP fusion protein produced in accordance with the method of claim 1. ### Claim 9 (depends on 4) The method of claim 4, wherein the bacterial cell is E. coli. ### Claim 10 (depends on 8) The conjugate vaccine of claim 8, wherein the vaccine comprises an adjuvant or carrier. ### Claim 11 (depends on 2) A conjugate vaccine comprising the glycosylated ComP fusion protein produced in accordance with the method of claim 2. ### Claim 12 (depends on 11) The conjugate vaccine of claim 11, wherein the vaccine comprises an adjuvant or carrier. ### Claim 13 (depends on 5) A conjugate vaccine comprising the glycosylated ComP fusion protein produced in accordance with the method of claim 5. ### Claim 14 (depends on 13) The conjugate vaccine of claim 13, wherein the vaccine comprises an adjuvant or carrier. ### Claim 15 (depends on 6) A conjugate vaccine comprising the glycosylated ComP fusion protein produced in accordance with the method of claim 6. ### Claim 16 (depends on 15) The conjugate vaccine of claim 15, wherein the vaccine comprises an adjuvant or carrier.